A Phase I/II, Double-Blind, Dose-Escalation Study to Evaluate the Safety and Antiviral Activity of IDX184 in Treatment-Naive Subjects Infected With Genotype 1 Chronic Hepatitis C.
Phase of Trial: Phase I/II
Latest Information Update: 15 May 2015
At a glance
- Drugs IDX 184 (Primary)
- Indications Hepatitis C
- Focus Adverse reactions
- Sponsors Idenix Pharmaceuticals; Merck Sharp & Dohme
- 15 Oct 2012 Results published in Antimicrobial Agents and Chemotherapy.
- 13 Nov 2009 Planned end date changed from 1 May 2009 to 1 Dec 2009 as reported by ClinicalTrials.gov.
- 02 Nov 2009 Results have been presented at AASLD 2009.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History